Scholarlink

Background <p>Multiple sclerosis (MS) is a chronic immune-mediated disease that can cause severe physical and cognitive disability. While modern therapies have improved outcomes in relapsing MS, patients with advanced disease remain underserved. In this stage, neurodegeneration dominates, treatment options are limited, and care becomes complex. Yet individuals with advanced MS are largely absent from trials, registries, and structured care pathways, leaving a major evidence gap.</p> Objectives <p>To characterize the clinical, social, and treatment-related profile of patients with advanced MS in institutional care.</p> Methods <p>We conducted an exploratory, retrospective study of patients with advanced MS (EDSS ≥ 6.5) admitted to a long-term care facility in Vienna. Data on disease history, comorbidities, medications, cognitive and functional status, and social background were extracted from medical records.</p> Results <p>Thirty-four patients were included (73.5% female; median age at admission: 54.1&#xa0;years). Most had secondary progressive MS (85.3%). Disease-modifying therapy (DMT) exposure was limited; only one patient received DMT during care. Comorbidity and polypharmacy were frequent. EDSS progression occurred in 50%. The Braden Scale was the only score differing significantly between cohorts.</p> Conclusions <p>This study highlights care gaps in advanced MS and the need for tailored strategies in institutional care settings.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advanced multiple sclerosis: an exploratory study on a neglected patient population

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月3日

查看全文
  • Omar Keritam,
  • Oliver Ascoli,
  • Andrea Harsanyi,
  • Hakan Cetin,
  • Thomas Berger,
  • Matthias Unseld,
  • Paulus Stefan Rommer

摘要

Background

Multiple sclerosis (MS) is a chronic immune-mediated disease that can cause severe physical and cognitive disability. While modern therapies have improved outcomes in relapsing MS, patients with advanced disease remain underserved. In this stage, neurodegeneration dominates, treatment options are limited, and care becomes complex. Yet individuals with advanced MS are largely absent from trials, registries, and structured care pathways, leaving a major evidence gap.

Objectives

To characterize the clinical, social, and treatment-related profile of patients with advanced MS in institutional care.

Methods

We conducted an exploratory, retrospective study of patients with advanced MS (EDSS ≥ 6.5) admitted to a long-term care facility in Vienna. Data on disease history, comorbidities, medications, cognitive and functional status, and social background were extracted from medical records.

Results

Thirty-four patients were included (73.5% female; median age at admission: 54.1 years). Most had secondary progressive MS (85.3%). Disease-modifying therapy (DMT) exposure was limited; only one patient received DMT during care. Comorbidity and polypharmacy were frequent. EDSS progression occurred in 50%. The Braden Scale was the only score differing significantly between cohorts.

Conclusions

This study highlights care gaps in advanced MS and the need for tailored strategies in institutional care settings.